SEC Comment Letter 0000000000-25-002881 to Petros Pharmaceuticals, Inc. (PTPI)
Petros Pharmaceuticals, Inc.
Date: March 17, 2025 · CIK: 0001815903 · Accession: 0000000000-25-002881
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-39752
Letter
Re: Petros Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14A Filed March 7, 2025 File No. 001-39752 Dear Fady Boctor:
March 17, 2025
Fady Boctor President and Chief Commercial Officer Petros Pharmaceuticals, Inc. 1185 Avenue of the Americas, 3rd Floor New York, New York 10036
We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation
Finance
Office of Life Sciences
cc: Alla Digilova, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 17, 2025 Fady Boctor President and Chief Commercial Officer Petros Pharmaceuticals, Inc. 1185 Avenue of the Americas, 3rd Floor New York, New York 10036 Re: Petros Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14A Filed March 7, 2025 File No. 001-39752 Dear Fady Boctor: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Alla Digilova, Esq. </TEXT> </DOCUMENT>